<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">348091</id>
  <title nil="true"/>
  <common-name>N-(2-bromo-4-methylphenyl)-2-[[5-(4-tert-butylphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide</common-name>
  <description>N-(2-bromo-4-methylphenyl)-2-[[5-(4-tert-butylphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide is a chemical compound with the formula C28H29BrN4O2S. With an average molecular weight of 565.50 g/mol, N-(2-bromo-4-methylphenyl)-2-[[5-(4-tert-butylphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide is a heavy molecule.</description>
  <cas>477313-56-7</cas>
  <pubchem-id>1582958</pubchem-id>
  <chemical-formula>C28H29BrN4O2S</chemical-formula>
  <weight>565.5</weight>
  <appearance nil="true"/>
  <melting-point nil="true"/>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility nil="true"/>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity nil="true"/>
  <metabolism nil="true"/>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity nil="true"/>
  <use-source nil="true"/>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2026-08-31T11:58:39Z</created-at>
  <updated-at type="dateTime">2026-08-31T11:58:39Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia nil="true"/>
  <uniprot-id nil="true"/>
  <kegg-compound-id nil="true"/>
  <omim-id nil="true"/>
  <chebi-id nil="true"/>
  <biocyc-id nil="true"/>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id nil="true"/>
  <pdb-id nil="true"/>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC1=CC(=C(C=C1)NC(=O)CSC2=NN=C(N2C3=CC=C(C=C3)OC)C4=CC=C(C=C4)C(C)(C)C)Br</moldb-smiles>
  <moldb-formula>C28H29BrN4O2S</moldb-formula>
  <moldb-inchi>InChI=1S/C28H29BrN4O2S/c1-18-6-15-24(23(29)16-18)30-25(34)17-36-27-32-31-26(19-7-9-20(10-8-19)28(2,3)4)33(27)21-11-13-22(35-5)14-12-21/h6-16H,17H2,1-5H3,(H,30,34)</moldb-inchi>
  <moldb-inchikey>JJYCJYITFQSDIY-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal" nil="true"/>
  <moldb-mono-mass type="decimal">564.11946</moldb-mono-mass>
  <origin nil="true"/>
  <state nil="true"/>
  <logp>7.2</logp>
  <hmdb-id nil="true"/>
  <chembl-id nil="true"/>
  <chemspider-id nil="true"/>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference nil="true"/>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM343984</chemdb-id>
  <dsstox-id nil="true"/>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id nil="true"/>
  <iupac>N-(2-bromo-4-methylphenyl)-2-[[5-(4-tert-butylphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide</iupac>
  <moldb-polar-surface-area nil="true"/>
  <moldb-refractivity nil="true"/>
  <moldb-polarizability nil="true"/>
  <moldb-rotatable-bond-count nil="true"/>
  <moldb-acceptor-count nil="true"/>
  <moldb-donor-count nil="true"/>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic nil="true"/>
  <moldb-physiological-charge nil="true"/>
  <moldb-number-of-rings nil="true"/>
  <moldb-alogps-logp nil="true"/>
  <moldb-alogps-logs nil="true"/>
  <moldb-alogps-solubility nil="true"/>
  <kingdom>Organic compounds</kingdom>
  <superklass>Organoheterocyclic compounds</superklass>
  <klass>Azoles</klass>
  <subklass>Triazoles</subklass>
  <paper-count type="integer" nil="true"/>
  <sync-id>CED0298426</sync-id>
  <structure-inchikey>JJYCJYITFQSDIY-UHFFFAOYSA-N</structure-inchikey>
  <structure-fingerprint>404000200000800000002800000000000000000000000000005000000000000000000000200004088000002080800000000000000000000000200000000000000000000000000000000000000020000000000100000200800010000000040000010000014040000000100000800000000100000000000000000004000000000040000000000000000000000080880000010000000080000000000000000000000000001000000000080000000040000000410000000000002c00000080000800000000000000000100000000400000000000002000000200000000000000008140000000800040020001000400000008010000000040000000000000</structure-fingerprint>
  <structure-pattern-fingerprint>7014c0008d32864081001b608138a3001800140087052010003d20c08224c94c6c022058139000001100410800c08082046002a4c08d3229016c653904a04010d7110c011290160800901040127202800804c58053213f3340040462400249040c29052f004c922060080480dd94024d208280720101c18e71180c6002710002104831184ef082080c0602504aac0098391d1a1244409e8a54000820604064a440d7301390b0c02000040960057c35104ac200028941084018204a104cc00272a04010a424d8103205808484541152910c010010030050200d720204280083009030491418c90160110a0013dd1220820050043080c2040e1108908072100606</structure-pattern-fingerprint>
  <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAAkAAAAJwAAAIABBgBgAAAAAQMGQCgAAAAD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</structure-pickle>
  <structure-indexed-at type="dateTime">2026-09-19T05:46:34Z</structure-indexed-at>
</compound>
